Plural, Cherry Ventures and Kindred Ventures led the financing. Other investors included LocalGlobe and Think.Health, plus existing investors APEX Ventures, participated. Brainlab contributed a strategic investment.

Paris-based Robeauté plans to use the funds to continue development and start human trials in 2026. It intends to set up U.S. operations ahead of FDA approval and full go-to-market efforts as well.

The company develops microrobots that come in at the size of a grain of rice. They can move along curved routes through the brain’s extracellular matrix to safely reach multiple sites of interest and carry out the required tasks. According to a news release, the company’s tiny, modular medical devices can embark on specific missions depending on the pathology.